JPH0729927B2
(ja)
*
|
1983-04-09 |
1995-04-05 |
日研化学株式会社 |
テオフィリン徐放性製剤
|
GB8514665D0
(en)
*
|
1985-06-11 |
1985-07-10 |
Eroceltique Sa |
Oral pharmaceutical composition
|
US4826688A
(en)
*
|
1985-11-13 |
1989-05-02 |
501 Elan Corporation PLC. |
Controlled absorption pharmaceutical formulation
|
GB2186485B
(en)
*
|
1986-02-13 |
1988-09-07 |
Ethical Pharma Ltd |
Slow release formulation
|
US4861598A
(en)
*
|
1986-07-18 |
1989-08-29 |
Euroceltique, S.A. |
Controlled release bases for pharmaceuticals
|
GB8626098D0
(en)
*
|
1986-10-31 |
1986-12-03 |
Euro Celtique Sa |
Controlled release hydromorphone composition
|
US4789549A
(en)
*
|
1987-03-09 |
1988-12-06 |
Warner-Lambert Company |
Sustained release dosage forms
|
US5079007A
(en)
*
|
1987-07-29 |
1992-01-07 |
The Upjohn Company |
Controlled release of antibiotic salts from an implant
|
GB8813064D0
(en)
|
1988-06-02 |
1988-07-06 |
Euro Celtique Sa |
Controlled release dosage forms having defined water content
|
JPH04504103A
(ja)
*
|
1988-07-01 |
1992-07-23 |
ファルマシア・アンド・アップジョン・カンパニー |
植込錠から制御放出される抗生物質塩
|
US5612059A
(en)
*
|
1988-08-30 |
1997-03-18 |
Pfizer Inc. |
Use of asymmetric membranes in delivery devices
|
ES2067957T3
(es)
*
|
1990-08-07 |
1995-04-01 |
Pfizer |
Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
|
JP2538134B2
(ja)
*
|
1991-04-08 |
1996-09-25 |
田辺製薬株式会社 |
徐放性製剤およびその製造法
|
US5266331A
(en)
*
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5478577A
(en)
*
|
1993-11-23 |
1995-12-26 |
Euroceltique, S.A. |
Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
|
US5958459A
(en)
*
|
1991-12-24 |
1999-09-28 |
Purdue Pharma L.P. |
Opioid formulations having extended controlled released
|
US5968551A
(en)
|
1991-12-24 |
1999-10-19 |
Purdue Pharma L.P. |
Orally administrable opioid formulations having extended duration of effect
|
SE9202250D0
(sv)
*
|
1992-07-29 |
1992-07-29 |
Gacell Lab Ab |
Controlled release morphine preparation
|
US20080075781A1
(en)
*
|
1992-11-25 |
2008-03-27 |
Purdue Pharma Lp |
Controlled release oxycodone compositions
|
US5656291A
(en)
*
|
1994-03-16 |
1997-08-12 |
Pharmacia & Upjohn Aktiebolag |
Controlled release preparation
|
SE9301057L
(sv)
*
|
1993-03-30 |
1994-10-01 |
Pharmacia Ab |
Beredning med kontrollerad frisättning
|
AU6552699A
(en)
*
|
1993-05-10 |
2000-03-02 |
Euro-Celtique S.A. |
Controlled release formulation
|
IL109460A
(en)
|
1993-05-10 |
1998-03-10 |
Euro Celtique Sa |
Controlled release formulation comprising tramadol
|
US20070275062A1
(en)
*
|
1993-06-18 |
2007-11-29 |
Benjamin Oshlack |
Controlled release oxycodone compositions
|
US7740881B1
(en)
|
1993-07-01 |
2010-06-22 |
Purdue Pharma Lp |
Method of treating humans with opioid formulations having extended controlled release
|
IL110014A
(en)
*
|
1993-07-01 |
1999-11-30 |
Euro Celtique Sa |
Solid controlled-release oral dosage forms of opioid analgesics
|
IL109944A
(en)
*
|
1993-07-01 |
1998-12-06 |
Euro Celtique Sa |
Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
|
US5879705A
(en)
*
|
1993-07-27 |
1999-03-09 |
Euro-Celtique S.A. |
Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
|
EP1442745A1
(en)
*
|
1993-10-07 |
2004-08-04 |
Euro-Celtique |
Orally administrable opioid formulations having extended duration of effect
|
KR100354702B1
(ko)
*
|
1993-11-23 |
2002-12-28 |
유로-셀티크 소시에떼 아노뉨 |
약학조성물의제조방법및서방형조성물
|
US5891471A
(en)
*
|
1993-11-23 |
1999-04-06 |
Euro-Celtique, S.A. |
Pharmaceutical multiparticulates
|
US5843480A
(en)
*
|
1994-03-14 |
1998-12-01 |
Euro-Celtique, S.A. |
Controlled release diamorphine formulation
|
AUPM814994A0
(en)
*
|
1994-09-14 |
1994-10-06 |
Sterling Winthrop Inc. |
Codeine-containing formulations
|
GB9422154D0
(en)
|
1994-11-03 |
1994-12-21 |
Euro Celtique Sa |
Pharmaceutical compositions and method of producing the same
|
US20020006438A1
(en)
*
|
1998-09-25 |
2002-01-17 |
Benjamin Oshlack |
Sustained release hydromorphone formulations exhibiting bimodal characteristics
|
US5965161A
(en)
|
1994-11-04 |
1999-10-12 |
Euro-Celtique, S.A. |
Extruded multi-particulates
|
GB9519363D0
(en)
*
|
1995-09-22 |
1995-11-22 |
Euro Celtique Sa |
Pharmaceutical formulation
|
US5811126A
(en)
*
|
1995-10-02 |
1998-09-22 |
Euro-Celtique, S.A. |
Controlled release matrix for pharmaceuticals
|
US5851555A
(en)
*
|
1997-08-15 |
1998-12-22 |
Fuisz Technologies Ltd. |
Controlled release dosage forms containing water soluble drugs
|
US6228863B1
(en)
*
|
1997-12-22 |
2001-05-08 |
Euro-Celtique S.A. |
Method of preventing abuse of opioid dosage forms
|
RS50070B
(sr)
|
1997-12-22 |
2009-01-22 |
Euro-Celtique S.A., |
Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
|
US20030091629A1
(en)
*
|
1998-03-27 |
2003-05-15 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
US20030118645A1
(en)
*
|
1998-04-29 |
2003-06-26 |
Pather S. Indiran |
Pharmaceutical compositions for rectal and vaginal administration
|
US6974590B2
(en)
|
1998-03-27 |
2005-12-13 |
Cima Labs Inc. |
Sublingual buccal effervescent
|
US20010038855A1
(en)
*
|
1998-06-05 |
2001-11-08 |
Desjardin Michael A. |
Dosage form for administering prescribed dose
|
US6806294B2
(en)
|
1998-10-15 |
2004-10-19 |
Euro-Celtique S.A. |
Opioid analgesic
|
DE19918325A1
(de)
|
1999-04-22 |
2000-10-26 |
Euro Celtique Sa |
Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
CA2389235C
(en)
|
1999-10-29 |
2007-07-17 |
Euro-Celtique, S.A. |
Controlled release hydrocodone formulations
|
JP2003522146A
(ja)
*
|
2000-02-08 |
2003-07-22 |
ユーロ−セルティーク,エス.エイ. |
外圧に抵抗性の経口オピオイドアゴニスト製剤
|
DE10029201A1
(de)
|
2000-06-19 |
2001-12-20 |
Basf Ag |
Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
|
DE10031043A1
(de)
*
|
2000-06-26 |
2002-02-14 |
Bayer Ag |
Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
|
EP2283829A1
(en)
|
2000-10-30 |
2011-02-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US20110104214A1
(en)
|
2004-04-15 |
2011-05-05 |
Purdue Pharma L.P. |
Once-a-day oxycodone formulations
|
UA81224C2
(uk)
*
|
2001-05-02 |
2007-12-25 |
Euro Celtic S A |
Дозована форма оксикодону та її застосування
|
ATE493130T1
(de)
|
2001-05-11 |
2011-01-15 |
Endo Pharmaceuticals Inc |
Opioid enthaltende arzneiform gegen missbrauch
|
US7052706B2
(en)
*
|
2001-06-08 |
2006-05-30 |
Nostrum Pharmaceuticals, Inc. |
Control release formulation containing a hydrophobic material as the sustained release agent
|
US20030068356A1
(en)
*
|
2001-07-10 |
2003-04-10 |
Pather S. Indiran |
Sequential drug delivery systems
|
DK1416842T3
(da)
*
|
2001-07-18 |
2009-03-16 |
Euro Celtique Sa |
Farmaceutiske kombinationer af oxycodon og naloxon
|
US20030044458A1
(en)
*
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
US20030157168A1
(en)
*
|
2001-08-06 |
2003-08-21 |
Christopher Breder |
Sequestered antagonist formulations
|
US20030068375A1
(en)
|
2001-08-06 |
2003-04-10 |
Curtis Wright |
Pharmaceutical formulation containing gelling agent
|
NZ530971A
(en)
|
2001-08-06 |
2004-08-27 |
Euro Celtique S |
Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists
|
US20030060422A1
(en)
|
2001-08-31 |
2003-03-27 |
Balaji Venkataraman |
Tannate compositions and methods of treatment
|
PE20030527A1
(es)
*
|
2001-10-24 |
2003-07-26 |
Gruenenthal Chemie |
Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
|
US7022342B2
(en)
|
2002-03-28 |
2006-04-04 |
Andrx Corporation, Inc. |
Controlled release oral dosage form of beta-adrenergic blocking agents
|
EP1492505B1
(en)
|
2002-04-05 |
2015-06-03 |
Euro-Celtique S.A. |
Pharmaceutical preparation containing oxycodone and naloxone
|
US7771707B2
(en)
|
2004-06-12 |
2010-08-10 |
Collegium Pharmaceutical, Inc. |
Abuse-deterrent drug formulations
|
AU2003270778B2
(en)
*
|
2002-09-20 |
2009-10-08 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
US20040202717A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
ITMI20032399A1
(it)
*
|
2003-12-09 |
2005-06-10 |
Zambon Spa |
Composizione farmaceutica contenente gabapentina.
|
JP5244318B2
(ja)
*
|
2003-12-31 |
2013-07-24 |
シーマ・ラブス、インコーポレイテッド |
発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法
|
PT1708686E
(pt)
*
|
2003-12-31 |
2011-04-20 |
Cima Labs Inc |
Forma de dosagem de fentanil oral efervescente geralmente linear e métodos de administração
|
WO2005065317A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Cima Labs Inc. |
Effervescent oral fentanyl dosage form
|
US20050226929A1
(en)
*
|
2004-04-12 |
2005-10-13 |
Jianbo Xie |
Controlled release opioid analgesic formulation
|
CA2565253A1
(en)
*
|
2004-05-21 |
2005-12-01 |
Alza Corporation |
Dosage form for delivery of multiple drug forms
|
EP1604666A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
US9308164B2
(en)
|
2004-06-30 |
2016-04-12 |
Sovereign Pharmaceuticals, Llc |
Hyoscyamine dosage form
|
US20060110439A1
(en)
*
|
2004-10-22 |
2006-05-25 |
Dynamis Therapeutics, Inc. |
Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
|
EP1702558A1
(en)
*
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1877040A1
(en)
*
|
2005-04-25 |
2008-01-16 |
Teva Pharmaceuticals USA, Inc. |
Extended release formulations
|
US20070160641A1
(en)
*
|
2006-01-12 |
2007-07-12 |
Eun-Hyun Jang |
Coated medical devices and methods of making the same
|
PT2034975E
(pt)
*
|
2006-06-19 |
2012-06-25 |
Alpharma Pharmaceuticals Llc |
Composições farmacêuticas
|
US20080075771A1
(en)
*
|
2006-07-21 |
2008-03-27 |
Vaughn Jason M |
Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
WO2009088673A2
(en)
*
|
2007-12-17 |
2009-07-16 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
US8623418B2
(en)
*
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
KR20130105935A
(ko)
*
|
2008-07-07 |
2013-09-26 |
유로-셀티큐 에스.에이. |
요폐의 치료를 위한 아편유사제 길항제의 용도
|
LT2405915T
(lt)
|
2009-03-10 |
2019-03-12 |
Euro-Celtique S.A. |
Greito atpalaidavimo farmacinė kompozicija, apimanti oksikodoną ir naloksoną
|
US10668060B2
(en)
|
2009-12-10 |
2020-06-02 |
Collegium Pharmaceutical, Inc. |
Tamper-resistant pharmaceutical compositions of opioids and other drugs
|
CA2690488C
(en)
*
|
2010-01-19 |
2013-06-11 |
Accucaps Industries Limited |
Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
|
CN104873455B
(zh)
|
2010-12-22 |
2023-09-12 |
普渡制药公司 |
包覆的抗篡改控制释放剂型
|
CN103327969A
(zh)
|
2010-12-23 |
2013-09-25 |
普渡制药公司 |
抗篡改固体口服剂型
|
CA3120681C
(en)
|
2012-04-17 |
2024-05-28 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
WO2014123899A1
(en)
|
2013-02-05 |
2014-08-14 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
US10751287B2
(en)
|
2013-03-15 |
2020-08-25 |
Purdue Pharma L.P. |
Tamper resistant pharmaceutical formulations
|
AU2014295042B2
(en)
|
2013-07-23 |
2017-03-30 |
Mundipharma Pty Limited |
A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
|
US9849124B2
(en)
|
2014-10-17 |
2017-12-26 |
Purdue Pharma L.P. |
Systems and methods for treating an opioid-induced adverse pharmacodynamic response
|
GB201420311D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Pharmaceutical processing
|
GB201420300D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Tablet
|
GB201420306D0
(en)
|
2014-11-14 |
2014-12-31 |
Bio Images Drug Delivery Ltd |
Compositions
|
US9737530B1
(en)
|
2016-06-23 |
2017-08-22 |
Collegium Pharmaceutical, Inc. |
Process of making stable abuse-deterrent oral formulations
|